To determine if the effect of ITZ on drug resistance was independent of androgen receptor (AR) activity, we investigated if ITZ could reverse DTX resistance in AR-negative ABCB1-overexpressing prostate cancer cell lines. This evidence concerns the gene AR and prostate carcinoma.